Atara Biotherapeutics, Inc. (ATRA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1150669,
    "name": "Atara Biotherapeutics, Inc.",
    "stock_name": "Atara Biotherapeutics, Inc.",
    "full_name": "Atara Biotherapeutics, Inc.",
    "name_url": "stocks-analysis/atara-biotherapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "14.20",
    "chg": 1.98,
    "chgp": "16.2%",
    "dir": 1,
    "prev_price": "12.22",
    "mcapval": "85.54",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US0465131078",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "254.77 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/atara-biotherapeutics-inc-1150669-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Atara Biotherapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-atara-biotherapeutics-inc-technically-bullish-or-bearish-3547422",
        "imagepath": "",
        "date": "2025-09-20 19:54:59",
        "description": "As of 12 August 2025, the technical trend for Atara Biotherapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe. However, the Dow Theory presents a mildly bearish outlook on both weekly and monthly timeframes, and the On-Balance Volume (OBV) is mildly bearish on the weekly but bullish on the monthly.\n\nIn terms of returns, the stock has outperformed the S&P 500 over the past year with a return of 53.37% compared to the S&P 500's 17.14%, but it has underperformed year-to-date with a return of -9.32% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the bullish signals in MACD and moving averages, despite some mixed indicators from Dow Theory and OBV...."
      },
      {
        "title": "Is Atara Biotherapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-atara-biotherapeutics-inc-overvalued-or-undervalued-3543798",
        "imagepath": "",
        "date": "2025-09-20 18:28:57",
        "description": "As of 4 May 2021, the valuation grade for Atara Biotherapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.14, an EV to EBITDA of 62.71, and an EV to Sales of 0.51. In comparison, peers such as Fusion Pharmaceuticals, Inc. have a P/E ratio of -17.5788 and an EV to EBITDA of -15.5851, while Emergent BioSolutions, Inc. shows a more attractive P/E of 2.9017 and an EV to EBITDA of 3.8058.\n\nDespite a strong one-year return of 53.37% compared to the S&P 500's 17.14%, the company's long-term performance has been significantly poor, with a three-year return of -88.05% versus the S&P 500's 70.41%. This suggests that while there may be short-term gains, the overall valuation remains questionable, reinforcing the view that Atara Biotherapeutics is overvalued...."
      }
    ],
    "total": 7,
    "sid": "1150669",
    "stock_news_url": "https://www.marketsmojo.com/news/atara-biotherapeutics-inc-1150669"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Atara Biotherapeutics, Inc. technically bullish or bearish?

2025-09-20 19:54:59

As of 12 August 2025, the technical trend for Atara Biotherapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe. However, the Dow Theory presents a mildly bearish outlook on both weekly and monthly timeframes, and the On-Balance Volume (OBV) is mildly bearish on the weekly but bullish on the monthly. In terms of returns, the stock has outperformed the S&P 500 over the past year with a return of 53.37% compared to the S&P 500's 17.14%, but it has underperformed year-to-date with a return of -9.32% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the bullish signals in MACD and moving averages, despite some mixed indicators from Dow Theory and OBV....

Is Atara Biotherapeutics, Inc. overvalued or undervalued?

2025-09-20 18:28:57

As of 4 May 2021, the valuation grade for Atara Biotherapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of -1.14, an EV to EBITDA of 62.71, and an EV to Sales of 0.51. In comparison, peers such as Fusion Pharmaceuticals, Inc. have a P/E ratio of -17.5788 and an EV to EBITDA of -15.5851, while Emergent BioSolutions, Inc. shows a more attractive P/E of 2.9017 and an EV to EBITDA of 3.8058. Despite a strong one-year return of 53.37% compared to the S&P 500's 17.14%, the company's long-term performance has been significantly poor, with a three-year return of -88.05% versus the S&P 500's 70.41%. This suggests that while there may be short-term gains, the overall valuation remains questionable, reinforcing the view that Atara Biotherapeutics is overvalued....

View All News